PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

Is PLUVICTO next in your prostate cancer journey?

For PSMA+ mCRPC after hormone therapy,

CONSIDER

PLUVICTO

NOW AVAILABLE *before* CHEMOTHERAPY*

Actor portrayal.

*For certain men as determined by their doctor.

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information on pages 13-14.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

Am I eligible? 3

What is PSMA? 4

What is PLUVICTO? 5

Why PLUVICTO?

- After hormone therapy 6
- After hormone therapy and chemotherapy 8

Questions to ask 10

Coverage 11

Novartis Patient Support™ 12

Important Safety Information 13

If your prostate cancer is progressing,

COULD PLUVICTO BE NEXT?

If you have already received

hormone therapy

OR

hormone therapy – & – chemotherapy

you could be eligible for **PLUVICTO**

If your cancer has spread outside the prostate and no longer responds to hormone treatment that lowers testosterone, PLUVICTO could be right for you.

Chemotherapy: Treatment that uses chemicals to kill fast-growing cells in the body. This includes cancer cells.
Hormone therapy: Treatment that interferes with the effects of testosterone.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 13-14.

If your PSA level rises,

IS IT TIME TO ASK ABOUT YOUR PSMA STATUS?

PSMA (prostate-specific membrane antigen) is a biomarker that can be found on prostate cancer cells and some normal cells. If you have higher levels of PSMA, you are considered PSMA+.

You can find out if you are PSMA+ by having an imaging test called a PSMA-PET scan.

>80%

of men with prostate cancer are PSMA+, and you could be too.
Find out your status to see if PLUVICTO could be right for you.

Biomarker: Something that can tell your doctor more about your cancer.
PSMA-PET scan: An imaging test that can find PSMA+ cells, including prostate cancer cells, in your body.

PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 13-14.

WHAT IS PLUVICTO?

PLUVICTO is not chemotherapy.

It is the FIRST and ONLY radioligand therapy (RLT) for PSMA+ mCRPC.

- RLT is a different type of radiation therapy that is injected or infused and targets the biomarker PSMA
- This means that it is designed to find and attack PSMA+ cells, including cancer cells*

*May also damage healthy PSMA+ and other nearby cells.

PLUVICTO is:

- Given through an intravenous (IV) injection or infusion
- Given every 6 weeks for up to 6 doses

mCRPC, metastatic castration-resistant prostate cancer.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see additional Important Safety Information on pages 13-14.

IF YOU'VE TRIED HORMONE THERAPY

The PSMAfore trial:
Included 468 men with PSMA+ prostate cancer that spread outside their prostate.

They were divided into 2 groups:

- 234 men were treated with PLUVICTO
  - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 234 men were treated with a second hormone therapy

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

Please see additional Important Safety Information on pages 13-14.

WHY PLUVICTO?

In the PSMAfore clinical trial, PLUVICTO was shown to provide benefits, including:

2x

More time without cancer worsening

Median radiographic progression-free survival (rPFS) was 9.3 months for men on PLUVICTO compared to 5.6 months on a second hormone therapy.

In an updated analysis 17 months later*:

- Median rPFS was **11.6 months** for men on PLUVICTO and **5.6 months** for men on a second hormone therapy

*Additional analysis conducted to learn more about rPFS in PLUVICTO patients.

Overall survival

Median overall survival (OS) was higher in patients who had PLUVICTO (24.5 months) compared to patients on a second hormone therapy (23.1 months). These results were not statistically significant.

49% of men

Had tumors shrink or disappear†

On PLUVICTO, **49%** of men saw their tumors shrink or disappear compared to **14%** with a second hormone therapy. That's 3.5 times as many.

This data point is called overall response rate (ORR), which is calculated by adding complete response (CR) and partial response (PR), which was:

- CR: **21%** with PLUVICTO vs **2.8%** with a second hormone therapy
- PR: **28%** with PLUVICTO vs **11%** with a second hormone therapy

†Measuring ORR was not the main goal of the PSMAfore trial. It was not statistically significant. It does not impact the results for rPFS.

IMPORTANT SAFETY INFORMATION (continued)

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information on pages 13-14.

IF YOU'VE TRIED HORMONE THERAPY AND CHEMOTHERAPY

The VISION trial:
Included 831 men with PSMA+ prostate cancer that spread outside their prostate.

They were divided into 2 groups:

- 551 men were treated with PLUVICTO plus standard therapy*
  - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 280 men were treated with standard therapy alone

*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (^{223}Ra), or drugs still being studied.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information on pages 13-14.

WHY PLUVICTO?

In the VISION clinical trial, PLUVICTO was shown to:

15 months

Help patients live longer

Median OS was **15.3 months** for men on PLUVICTO plus standard therapy compared to **11.3 months** on standard therapy alone.

9 months

Give people more time without cancer worsening

Median rPFS was **8.7 months** for men on PLUVICTO plus standard therapy compared to **3.4 months** on standard therapy alone.*

*rPFS results may be misread. In the clinical trial, many patients treated with standard therapy alone dropped out early.

49% of men

Help tumors shrink or disappear

On PLUVICTO plus standard therapy, **49%** of men saw their tumors shrink or disappear (ORR) compared to **1.6%** with standard therapy alone.

- CR: **9%** with PLUVICTO vs **0%** with standard therapy
- PR: **40%** with PLUVICTO vs **1.6%** with standard therapy

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 13-14.

Questions to ask

DURING YOUR DOCTOR VISIT

Having a clear understanding of PLUVICTO will help you and your doctor decide if it is right for you.

1. How will we know if PLUVICTO is right for me now?

2. Am I PSMA+? Do I need a PSMA-PET scan?

3. What are the next steps if this treatment is right for me?

Hear from other men about their journey.

Click or visit PLUVICTO.com to discover how.



IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin

Please see additional Important Safety Information on pages 13-14.

COVERAGE

When you and your health care provider have decided it's time for you to start treatment with PLUVICTO, here's what you'll need to know about PLUVICTO coverage.

PLUVICTO may be accessible to most insured men*

More than **80%** of insured men benefited from coverage for PLUVICTO as of January 2025

The other 20% of men do not have available policies and/or situations may be decided on an individual basis. Follow up with your plan to determine your coverage.

More than **8 out of 10** men covered paid $0 out of pocket per infusion

This is based on a study from 2023 to 2024. Approximately 85% of patients in the study paid $0 for PLUVICTO. Out-of-pocket costs for PLUVICTO for remaining patients vary. It may be as high as the full price of the product. There may also be added costs related to treatment, including but not limited to administration fees.

*This is not a guarantee of coverage. Patient out-of-pocket costs may vary. Coverage and reimbursement decisions vary.

This coverage data comes from patients who had taken hormone therapy and chemotherapy.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 13-14.

NOVARTIS PATIENT SUPPORT™

Once you and your health care provider decide to begin PLUVICTO, Novartis Patient Support is here to help.

We can help you:

Navigate the insurance process

Get financial support*

Find answers to questions across the treatment journey

If you have already been prescribed PLUVICTO, sign up for Novartis Patient Support.

Call 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays. Ask your health care provider to help you sign up for assistance.

Get financial support*

If you have private insurance, you could be eligible for Co-Pay Plus and **pay as little as $0** for your PLUVICTO treatment.

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare, Medicaid, or any other federal or state program. Offer subject to a maximum benefit per course of treatment. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms and Conditions in the enrollment forms for details.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see additional Important Safety Information on pages 13-14.

IMPORTANT SAFETY INFORMATION

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see full Prescribing Information here.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information here.

Over 20,000 men have already taken PLUVICTO

In your journey, how could PLUVICTO help?

Talk to your doctor about PLUVICTO today.

It could be your NEXT STEP.

Click or visit PLUVICTO.com to discover how.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

3/25 FA-11303686

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

Please see Important Safety Information on pages 13-14.